GCCL Signs Research Collaboration MOU with Seoul National University Neuropsychiatric Disorder Efficacy Evaluation Center

GCCL, a global clinical trial sample analysis organization, announced on September 22 that on the 19th, it signed a memorandum of understanding (hereinafter referred to as MOU) with the Seoul National University Neuropsychiatric Disorder Efficacy Evaluation Center for mutual cooperation to contribute to clinical research and the advancement of the pharmaceutical industry in the field of neuropsychiatric disorders.

GCCL and Seoul National University Neuropsychiatric Disorder Efficacy Evaluation Center signed an MOU for mutual cooperation in clinical research. Center Director Ki-Jung Chun (left) and GCCL CEO Kwan-Koo Cho (right) pose for a commemorative photo. GCCL

The signing ceremony was attended by CEO Kwan-Gu Cho of GCCL, Director Ki-Jung Chun of the Neuropsychiatric Disorder Efficacy Evaluation Center, and other representatives from both organizations. They reaffirmed their commitment to mutual cooperation aimed at enhancing the quality of domestic neuropsychiatric clinical trials, expanding clinical sample analysis infrastructure in the central nervous system (CNS) field, and strengthening global competitiveness.

The main points of the agreement include: ▲Strengthening collaboration between preclinical and clinical studies in the field of brain disorders; ▲Joint development of CNS disease biomarkers and analytical methods; ▲Joint operation of educational programs and exchange of technical and academic information; ▲Joint promotion and global expansion cooperation for "full-cycle CNS project support"; ▲Sharing and utilizing domestic and international networks, infrastructure, and resources; and ▲Other areas of mutual interest as needed.

The Neuropsychiatric Disorder Efficacy Evaluation Center, under Seoul National University Hospital, supports new drug development in the neuropsychiatric field and provides clinical consulting and efficacy evaluation services by utilizing the facilities and research infrastructure of Seoul National University Hospital and Seoul National University. GCCL offers comprehensive clinical trial sample analysis services required in this field and is at the forefront of developing CNS disease biomarkers and analytical methods.

Through this agreement, GCCL will be able to generate more precise and reliable research data by combining its capabilities with the clinical trial network of the Neuropsychiatric Disorder Efficacy Evaluation Center. In addition, it will enable full-cycle support for brain and CNS disease research, from preclinical to clinical stages.

Director Ki-Jung Chun of the Neuropsychiatric Disorder Efficacy Evaluation Center stated, "Research on neuropsychiatric disorders is a complex and challenging field, but securing high-quality clinical trial data determines the success or failure of therapeutic development. Through this agreement, domestic pharmaceutical and biotechnology companies and researchers will be able to utilize a global-level CNS clinical research environment more efficiently, which is expected to enhance the international standing of CNS research in Korea."

Kwan-Gu Cho, CEO of GCCL, said, "GCCL supports the success of clinical trials for domestic and international pharmaceutical and biotechnology companies in the CNS research field, based on the latest analytical platforms and high-quality analysis services. This strategic partnership with CLEVERcns will be an important step toward strengthening the overall capabilities of the CNS research ecosystem. GCCL will continue to prioritize data reliability and analytical quality, providing differentiated clinical trial sample analysis services in the global market."

Meanwhile, GCCL is a clinical trial sample analysis organization that has obtained certification in all areas of Good Clinical Laboratory Practice (GCLP) from the Ministry of Food and Drug Safety. It provides customized clinical analysis services that meet global standards for all phases of clinical trials, from Phase 1 to Phase 4. Based on various analytical platforms that meet global quality standards, such as the introduction of ddPCR equipment, and specialized sample analysis and analytical method development services, GCCL supports clinical trial sample analysis not only for domestic pharmaceutical and biotechnology companies but also for partners across Asia and worldwide.

This content was produced with the assistance of AI translation services.